These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29969601)

  • 1. Analysis of drug resistance mutations in whole blood DNA from HIV-1 infected patients by single genome and ultradeep sequencing analysis.
    Sotillo A; Sierra O; Martínez-Prats L; Gutiérrez F; Zurita S; Pulido F; Rubio R; Delgado R
    J Virol Methods; 2018 Oct; 260():1-5. PubMed ID: 29969601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1C proviral DNA for detection of drug resistance mutations.
    Huruy K; Mulu A; Liebert UG; Maier M
    PLoS One; 2018; 13(10):e0205119. PubMed ID: 30286160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 proviral resistance mutations: usefulness in clinical practice.
    Kabamba-Mukadi B; Duquenne A; Henrivaux P; Musuamba F; Ruelle J; Yombi JC; Bodéus M; Vandercam B; Goubau P
    HIV Med; 2010 Sep; 11(8):483-92. PubMed ID: 20163482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase.
    Yin QQ; Li ZP; Zhao H; Pan D; Wang Y; Xu WS; Xing H; Feng Y; Jiang SB; Shao YM; Ma LY
    Biomed Environ Sci; 2016 Apr; 29(4):239-47. PubMed ID: 27241734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Comparative Analysis of Pre-existing HIV Drug Resistance Mutations in Proviral DNA Using Next-Generation Sequencing and Routine HIV RNA Genotyping.
    Gaitan NC; D'Antoni ML; Acosta RK; Gianella S; Little SJ; Chaillon A
    J Acquir Immune Defic Syndr; 2023 Jul; 93(3):213-218. PubMed ID: 36961945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men.
    Chaillon A; Nakazawa M; Wertheim JO; Little SJ; Smith DM; Mehta SR; Gianella S
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
    Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
    AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proviral DNA as a Target for HIV-1 Resistance Analysis.
    Lübke N; Di Cristanziano V; Sierra S; Knops E; Schülter E; Jensen B; Oette M; Lengauer T; Kaiser R
    Intervirology; 2015; 58(3):184-9. PubMed ID: 26139571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV drug resistance mutations in proviral DNA from a community treatment program.
    Derache A; Shin HS; Balamane M; White E; Israelski D; Klausner JD; Freeman AH; Katzenstein D
    PLoS One; 2015; 10(1):e0117430. PubMed ID: 25635815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relevance of ultradeep sequencing for low HIV-1 viral loads and proviruses in the clinical setting.
    Foury A; Saunier A; Taverniers A; Pinet N; Josse T; Jeanmaire E; Emilie C; Schvoerer E; Hartard C
    J Med Virol; 2024 Aug; 96(8):e29870. PubMed ID: 39185639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing.
    Huber M; Metzner KJ; Geissberger FD; Shah C; Leemann C; Klimkait T; Böni J; Trkola A; Zagordi O
    J Virol Methods; 2017 Feb; 240():7-13. PubMed ID: 27867045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Aspects of the Virus Life Cycle and Clinical Utility of Next Generation Sequencing based HIV-1 Resistance Testing in the Genomic, the Proviral, and the Viral Reservoir of Peripheral Blood Mononuclear Cells.
    Pröll J; Paar C; Taylor N; Skocic M; Freystetter A; Blaimschein A; Mayr R; Niklas N; Atzmüller S; Raml E; Wechselberger C
    Curr HIV Res; 2022; 20(3):213-221. PubMed ID: 35331114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay.
    Alidjinou EK; Coulon P; Hallaert C; Robineau O; Meybeck A; Huleux T; Ajana F; Hober D; Bocket L
    J Clin Virol; 2019 Dec; 121():104207. PubMed ID: 31707202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights about minority HIV-1 strains in transmitted drug resistance mutation dynamics and disease progression.
    Leda AR; Hunter J; Oliveira UC; Azevedo IJ; Sucupira MCA; Diaz RS
    J Antimicrob Chemother; 2018 Jul; 73(7):1930-1934. PubMed ID: 29684141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
    Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
    Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.